Approximately 60 years ago in England, phototherapy for neonatal hyperbilirubinemia was used in clinical practice. It was introduced in Japan approximately 50 years ago. At that time, the mechanism underlying the serum bilirubin concentration decrease by phototherapy was still unknown. The mechanism was identified by chemists, biochemists, and pediatricians. Clarification started with the report that unconjugated bilirubin was excreted into bile after photoirradiation in Gunn rats. After confirmation of the molecular structure of bilirubin on X-ray analysis, the mechanism for bile excretion of unconjugated bilirubin was verified based on geometric configurational photoisomers in the Gunn rat. Finally, the reaction and excretion of structural bilirubin photoisomers was proved to be the main mechanism for the decrease in serum bilirubin during phototherapy for neonatal hyperbilirubinemia, which differs from the mechanism in the Gunn rat. The most effective and safest light source and the optimal method to evaluate phototherapy, however, remain unknown. Moreover, as for bronze baby syndrome, which is a well-known adverse reaction to phototherapy, the etiology is unclear. Hence, we review phototherapy for hyperbilirubinemia including a fundamental understanding of the bilirubin photochemical reactions, and discuss the subclinical carcinogenic risk of phototherapy and the increased mortality rate of extremely low-birthweight infants due to aggressive phototherapy, which is becoming an increasing problem.
reported that bilirubin oxidization was a minor pathway in vivo in 1984, and research on the oxidative reactions of bilirubin, believed to be the main mechanism at that time, was ceased. After the molecular conformation of bilirubin, research turned to the photochemical reaction of bilirubin in a tetrapyrrolic state. Based on PubMed, the last basic bilirubin photochemical study on phototherapy for neonatal hyperbilirubinemia, including the pathway of the photochemical reaction, was reported by Ennever and Dresing in 1991. 5 In contrast, the subclinical carcinogenic risk in vitro of phototherapy has been investigated since 1970. In the clinical field, however, the adverse reaction to phototherapy is widely known as bronze baby syndrome, and other critical adverse reactions have not been reported until the present. Recently, an epidemiologic survey reported that the risk of childhood cancer was increased by previous phototherapy, 6, 7 and the mortality rate among infants weighing 501-750 g at birth was increased by aggressive phototherapy. 8 From these reports, phototherapy may be positioned similarly to drug therapy. 9 In order to verify its effectiveness and safety, it is important to continuously develop the light sources and irradiation methods based on photochemical reaction (like drug dosage and treatment) and discuss the methods to evaluate these phototherapy instruments (like therapeutic drug monitoring).
Geometric configurational bilirubin photoisomers
The chemical name of bilirubin is 1,10,19,21,23,24-hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-devinylbilin-8, 12-dipropanoic acid, or 8,12-bis(2-carboxyehyl)-10,21,23,24-tetrahydro-2,7,13,17-tetramethyl-3,18-deivinyl-bilin-1,19-dion, or 8,12-bis(carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinyl (10H, 21H,24H)bilin-1,19-dione or 2,17-deiethenyl-1,10,19,22,23, 24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-biline-8, 12-dipropanoic acid. 10 Although the plane structure and molecular weight are clear, we could not explain the hydrophobic character of bilirubin despite the existence of many polar groups (2 carbonyl, 4 imino, 2 carboxyl). This was resolved by the X-ray analysis of Bonnett et al. 3 in 1976. The polar groups are confined inside the bilirubin molecule by intramolecular hydrogen bonds and the surface structure has only hydrophobic groups (4 methyl, 2 vinyl; Fig. 1 ). Generally, the structural formula is shown omitting intramolecular hydrogen bonds (Fig. 2) . The possibility of cis and trans (Z and E) geometric isomerization about the meso carboncarbon double bonds at C 4 -C 5 and C 15 -C 16 of bilirubin was recognized by Lemberg in 1939. 13 In order to develop the structure reported by Bonnett et al., which forms intramolecular hydrogen bonds, it must have a Z configuration. Therefore, the trivial name of bilirubin in consideration of the stereoisomeric form is (ZZ)-bilirubin. The geometric photoisomers of (ZZ)-bilirubin are: (ZE)-bilirubin, (EZ)-bilirubin, and (EE)-bilirubin (Fig. 3) . 14 The dynamics of the geometric isomers under light irradiation to each bilirubin solution are as follows: (ZE)-/(EZ)-bilirubin in dimethyl sulfoxide reaches a photoequilibrium with (ZZ)-bilirubin within 1 min of light irradiation at 11.8 lW/cm 2 / nm. 15 The (ZE)-bilirubin/(ZZ)-bilirubin ratio in bilirubin-human serum albumin solution reaches a state of photoequilibrium as irradiation time is prolonged, irrespective of the amount of irradiation energy. 16 
Structural (constitutional) bilirubin photoisomers
Regarding structural isomerization (intermolecular dipyrrole exchange), bilirubin-IXa can rearrange in various acid catalytic solutions to a mixture of bilirubin-IIIa, -IXa, and -XIIIa (Fig. 4) . This isomerization reaction caused many erroneous results in vitro, 17 but this reaction plays no important role in bilirubin photoisomerization in vivo.
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The main structural bilirubin photoisomers in phototherapy for neonatal hyperbilirubinemia were detected on separation analysis methods such as thin layer chromatography (TLC) 19 and high-performance liquid chromatography (HPLC), [20] [21] [22] [23] and the reaction materials were identified. The structural photoisomer was first identified by McDonagh and Palma using 1 H nuclear magnetic resonance (NMR) spectra (Fig. 5) , 24 but two structural isomers were possible with their method, and Bonnett et al. 19 confirmed the most likely structure using infrared-absorption spectra. Onishi et al. 25 identified the same structure based on 1 H-and 13 C-NMR spectra in the same period as Bonnett et al. 19 Despite using the same structural formula, the nomenclature was different. McDonagh and Palma, Bonnett et al., and Onishi et al. named it (Z)-lumirubin, 24 photobilirubin IIA, 19 and (EZ)-cyclobilirubin, 25 respectively. Moreover, the geometric photoisomer with an E-conformation in the double bond of C 15 -C 16 , was named (E)-lumirubin, 24 photobilirubin IIB, 19 and (EE)-cyclobilirubin, 25 respectively. Regarding the reaction pathway from (ZZ)-bilirubin to (EZ)-cyclobilirubin in the bilirubin-human serum albumin complex, McDonagh et al. 24, 26 reported that (EZ)-cyclobilirubin was generated directly from (ZZ)-bilirubin. Itoh and Onishi, Bonnett and Ioannou, and Ennever and Dresing, however, verified 3 The molecule takes the form of a ridge tile along the line C 8 -C 10 -C 12 . Thus, rings A and B are in one plane and rings C and D are in another, with an interplanar angle (h) of approximately 98°. Therefore, two enantiomers exist in (ZZ)-bilirubin. On circular dichronism the structure of albumin-bound bilirubin has right-handed chirality. 12 In the present review, these two enantiomers are indistinguishable, therefore we used (ZZ)-bilirubin because separation analysis of the two enantiomers has not been conducted. (d) Crystal structure 3 and enantiomer. that (EZ)-bilirubin was an intermediate in photochemical changes from (ZZ)-bilirubin to (EZ)-cyclobilirubin using a kinetic method, 27 (Z)-vinylneoxanthobilirubic acid, 28 and purified (EZ)-bilirubin, 5 respectively. The dynamic states of (EZ)-cyclobilirubin in the dimethyl sulfoxide solution of bilirubin 15 and in the bilirubin-human serum complex solution 16 show a dose-response relationship between irradiation time and production of (EZ)-cyclobilirubin, and between the light dose and (EZ)-cyclobilirubin production, respectively. The relationship between (EZ)-cyclobilirubin and (EE)-cyclobilirubin in the bilirubin-human serum albumin complex solution is a state of photoequilibrium, the same as that between (ZZ)-bilirubin and (ZE)-bilirubin. 23 
Mechanism of phototherapy for human neonatal hyperbilirubinemia
Early in vivo research elucidated the production and excretion of bilirubin photoisomers on light irradiation of Gunn rats. Ostrow found that unconjugated bilirubin was excreted into bile on photoirradiation of Gunn rats. 29 The biological importance of the geometric configurational photoisomerization of 10 Photobilirubin is a mixture of (ZE)-/(EZ)-/(EE)-bilirubin. Additional recognizable stereochemical features may be found through rotations about the carbon-carbon single bonds between 5 and 6, 9 and 10, and 14 and 15. When imposed on the configurational isomers recognized, two more forms are obtained for each Z and E isomer. This is true because the focal points, the N atoms, may appear near (syn) or distant from (anti) each other in the planar projection. 10 Given, however, that the distinction of syn-and anti-is not possible using analytical methods, we used the notation (ZZ)-
(ZZ)-bilirubin to photobilirubin (mixture of (ZE)-, (EZ)-, and (EE)-bilirubin) in this phenomenon was first reported by McDonagh and Ramonas. 30 This phenomenon was proved on HPLC of the exact geometric bilirubin photoisomers. 22 The results using Gunn rats, however, differed from those in human newborn infants. The main form of bilirubin excreted into bile during phototherapy was the geometric isomer in Gunn rats 22, 31 and the structural isomer in human newborn infants. 32 This was proved by analyzing the bilirubin photoisomers in bile during photoirradiation. The former was mainly excreted in bile through (ZE)-/(EZ)-bilirubin and the latter was mainly excreted in bile and urine through (EZ)-/(EE)-cyclobilirubin (Fig. 6) . 32 The reason for the difference in the production of these photoisomers depends on the species difference of the serum albumin, which forms a complex with bilirubin. 24, 27, 33 The differences in the photo-equilibrium between (ZE)-/(EZ)-bilirubin and (ZZ)-bilirubin and the production of (EZ)-/(EE)-cyclobilirubin were due to species differences in the serum albumin, and the bilirubin-human serum albumin complex generated (EZ)-/(EE)-cyclobilirubin more efficiently than bilirubin-serum albumin of other species. 34 (ZE)-Bilirubin is a photoisomer that exists the most abundantly in the serum of human newborn infants before and during phototherapy. 32 In contrast, (EZ)-/(EE)-cyclobilirubin is increased by only a small amount in human neonatal serum during phototherapy in vivo, 32 although (EZ)-/(EE)-cyclobilirubin in bilirubin-human serum complex solution increased with the photoirradiation time in vitro. 15, 16 This is explained by the fact that the overall elimination of (EZ)-/(EZ)-cyclobilirubin into bile was far more rapid than that of (ZE)-bilirubin. 35, 36 (ZE)-Bilirubin returns to (ZZ)-bilirubin in bile and is reabsorbed from the intestinal tract into the enterohepatic circulation. Moreover, blue light-emitting diode (LED) is widely used as a light source for phototherapy in Japan. There is sufficient cyclobilirubin production on blue LED phototherapy in vitro, but high-level production of (ZE)-bilirubin occurs at the same time. 37 This may reduce the effect of phototherapy in vivo because (ZE)-bilirubin may compete with cyclobilirubin for liver uptake. Therefore, (ZE)-bilirubin will be inefficiently excreted out of the body during phototherapy.
The development of phototherapy instruments for human hyperbilirubinemic neonates using the concept described in the previous section is important in clinical practice. For that purpose, it is necessary to identify the wavelength that generates (EZ)-cyclobilirubin the most efficiently. Onishi et al. and Itoh et al. 38, 39 found that the most efficient wavelength was 500-520 nm in the green region. Ennever and Dresing reached the same conclusion by calculating the quantum yield for the formation of (EZ)-cyclobilirubin from (EZ)-bilirubin. 5 The basis of the clinical effect of green light phototherapy has been confirmed, 40, 41 and a clinical effect has been confirmed using LED light closer to monochromatic light. 42, 43 The development of a radiometer to evaluate light sources, however, is not progressing, and evaluation has to be carried out in consideration of light sources with several wavelengths, reported by Kuboi et al. 44 (ZE)-Bilirubin, which is less markedly generated using the long wavelength region of visible light, 39 has to be re-evaluated regarding its in vivo effect in phototherapy for human neonatal hyperbilirubinemia. 42 
Adverse reactions of phototherapy for neonatal hyperbilirubinemia
Important adverse reactions of phototherapy for neonatal hyperbilirubinemia include the subclinical carcinogenic risk, the effect of aggressive phototherapy on extremely low-birthweight (ELBW) infants, 8 and bronze baby syndrome. 45 
Subclinical carcinogenic risk and effect of aggressive phototherapy in ELBW infants
Many in vitro studies have reported on the subclinical carcinogenic risk using a conventional light source. It was thought that a wavelength 400-450 nm, which induces the photosensitization of riboflavin, an endogenous substance, would pose a problem in phototherapy. [46] [47] [48] [49] Serious adverse reactions, however, were not reported in phototherapy using blue light including the white light generally used in clinical field, possibly because of the shielding effect of the Soret band of the hemoglobin at wavelengths of 400-500 nm. 50 The same authors from California recently published two papers on an epidemiologic survey of phototherapy. The first report focused on the onset of cancer in infants under 1 year of age. 6 Those who received phototherapy were 1.6-fold more likely to develop cancer (95%CI: 1.2-2.0; P = 0.002). The second focused on children diagnosed with cancer at any age. 7 The crude data suggested an increased risk following phototherapy (relative risk, 1.4). Furthermore, Morris et al. 8 randomly assigned 1,974 ELBW infants (≤1,000 g) at 12-36 h of age to either aggressive or conservative phototherapy. The mortality rates were 39% with aggressive phototherapy and 34% with conservative phototherapy for infants with birthweight 501-750 g (relative risk. 1.13; 95% CI: 0.96-1.34). Morris et al. 8 hypothesized about the difference in the mortality rate due to antioxidant levels or oxidative injury. In a clinical setting, however, in such small infants often need higher inotropes or fluid to maintain appropriate circulation during phototherapy.
Given that a new phototherapy light source that does not produce wavelengths 400-450 nm and is clinically effective 42, 43 has been developed and the radiometer can evaluate the energy of the light source based on the theoretical evidence of phototherapy for neonatal hyperbilirubinemia, 44 it is necessary to examine whether such adverse reactions will decrease using them. The adverse reactions of green light phototherapy include effects on the observer's vision 51 and the phototoxicity of bilirubin to human cells in vitro. 52 We reported that the optical stimulus could be reduced by adding a complementary color light (pink light) to the green light, 51 and the mutagenicity caused by green light was less than that by blue light in vitro. 53 The bilirubin phototoxicity on human cells caused by green light may arise from singlet oxygen via the photochemical reaction of (EZ)-cyclobilirubin. 52 (EZ)-Cyclobilirubin is generated by not only green light but also by blue light, 51 and it is not accumulated in the physiological state. 35, 36 Especially, in phototherapy for ELBW infants, the phototheraphy light source must be selected to ensure the correct light wavelength and light energy level, because the capacity of ELBW infants for (EZ)-/(EE)-cyclobilirubin elimination, and the antioxidant level, are low. [53] [54] [55] Furthermore, ELBW infants also required high-level hemodynamic management accompanying phototherapy.
Bronze baby syndrome
In 1972, Kopelman et al. 45 first reported bronze baby syndrome as an adverse reaction to phototherapy in hyperbilirubinemic neonates. In 1971 at the 74th Annual Meeting of the Japan Pediatric Society, however, Onishi had already reported a patient with the greenish-brown tone of serum as an adverse reaction to phototherapy in hyperbilirubinemic neonates, and considered that it was related to methohemalbumin or biliverdin. 56 Kopelman et al. 45 considered the accumulation of photo-oxidation substances of bilirubin as the origin, because neonates with the symptoms of bronze baby syndrome were complicated by obstructive jaundice. In 1978, Onishi conducted an analysis of the predisposing factors and the bronze pigment of bronze baby syndrome. 57 Using a questionnaire to analyze the predisposing factors, the complication rate of obstructive jaundice was the highest (Table) . 57, 58 On analysis of the bronze pigments, the molecular weight was >600 Da on gel-permeation chromatography. Thus, the bronze pigments were considered to be polymerization products caused by the free radical reactions of the degradation products of bilirubin (dyprromethene) due to phototherapy. 57 Thereafter, we succeeded in the separation of bilirubin photoisomers on reversed-phase HPLC. 20 Based on that analysis, the peak retention time was shorter than the peak of (ZE)-/(EZ)-bilirubin, and we named it the unknown pigment. 15 We also reported that neonates with symptoms of bronze baby syndrome had higher levels of the unknown pigment in the serum than other hyperbilirubinemic neonates without bronze baby syndrome during phototherapy. 59 The structure of the unknown pigment was determined on 1 H-and 13 C-NMR and mass spectrometry, and named (EZ)-cyclobilirubin. 25 This substance has the structure of the azacyclopentadiene ring, and von Dobeneck reported that the structure could promote free radical reaction polymerization. 60 The copper porphyrin theory was reported by Rubaltelli et al. 61 in 1983, and many studies on the theory were reported after that. 62, 63 The evidence to support the copper porphyrin theory is based on a peculiar peak at ≥500 nm (kmax, 585, 619, 670 nm) identified on spectral analysis of the samples from bronze baby syndrome. Porphyrin in the samples was analyzed, two kinds of Cu 2+ -proto and Cu 2+ -coproporphyrin were found, and Cu 2+ -uroporphyrin was detected in the aqueous layer on TLC. Copper and porphyrin in the blood increased with the obstruction of the biliary tract, combined, and a copper-porphyrin complex was formed. It was hypothesized that the copper-porphyrin complex changed to a brown color with the photosensitization of bilirubin by light irradiation. They proved those processes based on the absorption and fluorescence spectra. This hypothesis, and the analytical methods, however, were associated with some problems: bilirubin becomes a photosensitizer and Cu 2+ -porphyrin is degraded by the effects of photosensitizers. 10, 64 We examined whether the copper-protoporphyrin complex would accelerate the generation of (EZ)-/(EE)-cyclobilirubin and polymerization of cyclobilirubin, and the results were negative (data not shown). Moreover, McDonagh examined whether bilirubin would change the copper-porphyrin complex with the absorption spectrum, and proved that the phenomenon does not exist. 64 Therefore, the copper-porphyrin complex does not influence the development of bronze baby syndrome in neonates.
Given, however, that the etiology of bronze baby syndrome is unclear, 65 we must identify the photoproducts when treating bronze baby syndrome. We believe that the cause of the bronze color is the polymerized substances of bilirubin photoisomers and that those substances accumulate in the body of the neonatal infant. 66 We consider that the double bond between N of the B ring of (EZ)-/(EE)-cyclobilirubin and C 6 breaks, and that C 6 of (EZ)-/(EE)-cyclobilirubin covalently binds to N of both sides of the end ring of the E-type photoisomers and they polymerize (Fig. 7) .
Conclusion
In conclusion, the most effective wavelength of phototherapy for human neonatal hyperbilirubinemia lies near the green region rather than the blue region. Based on this idea, we are able to perform safer phototherapy by avoiding the wavelength 400-500 nm, which belongs to the blue region and which can be harmful. The current method to assess light energy in phototherapy is limited to that for blue light, therefore it is necessary to develop a new method for evaluation and comparison of light sources other than blue light. The control of light energy in consideration of the excretion dynamic state of (EZ)-/(EE)-cyclobilirubin and the antioxidant action of bilirubin is required for phototherapy, especially in that for ELBW infants.
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